Compounded Tirzepatide Real Results: Weight Loss Timeline & What Patients Report
Introduction
Average weight loss on tirzepatide from SURMOUNT-1 (Jastreboff et al. 2022, NEJM): about 5% at week 12, 12-15% at week 28, and 19.5-20.9% at week 72 on the 10-15 mg doses. The trial enrolled 2,539 adults with overweight or obesity but without diabetes, and is the foundation for FDA approval of Zepbound® for weight management.
Individual results vary widely. About 91% of SURMOUNT-1 participants on 15 mg lost ≥5% of body weight, 73% lost ≥15%, 57% lost ≥20%, and 36% lost ≥25%. The placebo group averaged 3.1% loss over the same period.
This article maps each phase, what changes in appetite and energy, and what puts someone above or below the average curve.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
What Happens in the First 4 Weeks?
The 2.5 mg starter dose is sub-therapeutic for weight loss. Average loss in weeks 1-4 is 2-4 pounds. Some people lose nothing in month one. Most early loss is water and inflammation rather than fat.
Quick Answer: SURMOUNT-1 average weight loss: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) at 72 weeks
What you do notice is appetite changes. Within 2-3 days of the first injection, snack cravings ease and meals end faster. Most patients describe stronger appetite suppression on tirzepatide compared to semaglutide reports.
Bottom line for month one: don’t judge the drug by the scale yet. The dose is intentionally low to build tolerance. Real weight loss begins once titration crosses 5 mg in week 5.
What Does Month 2 (Weeks 5-8) Look Like?
The 5 mg dose is the first fully therapeutic level. Average SURMOUNT-1 loss through week 8 was 5-7% of body weight, roughly 11-15 pounds from 220. Weekly drops of 1-3 pounds become typical.
Appetite suppression deepens noticeably. Most patients eat 30-50% less than baseline portions without effort. Clothing fit changes start showing up around week 6-8. Waist measurements often drop faster than total weight because visceral fat goes first.
Side effects from the dose increase are normal in days 1-7 of week 5. Nausea, fatigue, and digestive shifts usually resolve by day 10. If they don’t, holding at 5 mg longer is the right call.
What About Months 3-4 (Weeks 9-16)?
Weeks 9-12 on 7.5 mg usually produce the fastest weight-loss phase. Average SURMOUNT-1 loss through week 12 was 8-11% of body weight, or 18-24 pounds from 220. The curve is steepest here.
Weeks 13-16 on 10 mg often shows continued strong loss. By week 16, averages reached 14-16%, about 31-35 pounds from 220. This is where many people first hit measurable health improvements: lower fasting glucose, lower blood pressure, less joint pain, better sleep apnea symptoms.
Some patients hit goal weight around month 4 if they started closer to overweight rather than obese ranges. Many choose to hold at 10 mg rather than escalate further.
What Happens at Months 5-8 (Weeks 17-32)?
Once on a stable maintenance dose (10, 12.5, or 15 mg), the rate of loss slows but continues. SURMOUNT-1 averages went from 14% at week 16 to about 17-19% at week 28 on the higher doses.
This is the phase where habits matter most. The drug suppresses appetite, but protein intake, strength training, sleep, and stress all influence whether the energy deficit translates to fat loss or muscle loss. Aim for 1.2-1.6 g protein per kg body weight per day and 2-3 resistance training sessions weekly.
Many patients see the second wave of visible change here. Face shape changes, jawline definition returns, clothing sizes drop multiple times. Body composition (DEXA or smart scale) shows fat percentage dropping while lean mass holds when nutrition and training are in line.
What About Months 9-12 (Weeks 33-52)?
Average SURMOUNT-1 loss reached 18-21% by week 52 depending on dose. Rate slows to about 0.3-0.7 pounds per week. Some patients experience their first true plateau at month 9-10 where the scale doesn’t move for 3-4 weeks at a time.
Plateaus are biologically normal. The body’s resting metabolic rate falls as weight drops. Hormonal adaptations including reduced leptin and increased ghrelin sensitivity also occur. Pushing through a plateau means a dose review, a hard look at intake and protein, and sometimes a brief diet break to reset.
By month 12, someone starting at 220 pounds has lost about 40-46 pounds on average. That’s enough to push down BMI category, often reverse prediabetes, and substantially improve sleep apnea.
What Does the Second Year Look Like?
SURMOUNT-1 followed patients through week 72 (about 17 months). Average loss plateaued around week 60-70 with continued small gains. Year 2 data are still being collected and published as the original trial extended into open-label extension.
In practical terms, year 2 is maintenance with small additional losses if you’re still pursuing them. Most weight comes off in year 1. Year 2 is about consolidating habits, refining body composition, and finding the lowest effective maintenance dose.
Many patients explore lower maintenance doses (5 mg or 7.5 mg) during year 2 with provider supervision. There’s no strong evidence base for tapering protocols, but clinical practice has moved toward “lowest effective dose” rather than maximum lifetime.
What Predicts Faster or Slower Results?
The biggest predictor is dose escalation completion and adherence. People who reach 10-15 mg and stay there lose more than those who hold at lower doses. The second predictor is protein intake. People in the top quartile of protein consumption preserve about 2-3% more lean mass.
Resistance training matters. People who lift weights 2-3x weekly preserve more lean mass and end up with better body composition at the same weight. Sleep under 7 hours per night reliably slows weight loss by 15-20% across multiple obesity trials.
Genetics, baseline insulin resistance, and gut microbiome differences also matter but aren’t easily modifiable. Women in perimenopause may lose slightly slower due to hormonal shifts. Men typically lose faster initially but plateau at similar relative percentages.
Key Takeaway: Weight loss accelerates from week 8-12 once titration reaches therapeutic doses
What If You’re Not Losing Weight?
About 9% of SURMOUNT-1 participants on 15 mg failed to reach the 5% weight loss threshold. The most common reasons are inadequate dose progression, food intake that hasn’t dropped despite reduced appetite, and conditions like untreated hypothyroidism or PCOS that need separate management.
Action steps if the scale isn’t moving after 12 weeks on 10-15 mg: log food intake for a week to verify the deficit is real, check thyroid function (TSH) and other hormones, review sleep and stress, and discuss whether escalation or switching is appropriate.
TrimRx providers review progress at regular intervals as part of the personalized treatment plan. If your trajectory is well below average, the plan can adjust before the issue becomes a longer-term stall.
What Happens When You Stop?
SURMOUNT-4 (Aronne 2024 JAMA) tested whether continued tirzepatide vs switching to placebo affects maintenance. After 36 weeks of titration, 670 participants continued or switched. The continuation group lost another 5.5% over the next year. The placebo switch group regained 14.0%.
That regain pattern, about two-thirds of lost weight back over the year after stopping, is consistent with other GLP-1 drugs and with most weight-loss interventions including bariatric surgery and lifestyle programs.
This is why obesity is treated as a chronic relapsing condition and why most clinical guidance now favors long-term GLP-1 use rather than short courses. Some people maintain after stopping if they’ve built strong habits, but the majority will regain.
What Does the Body Composition Story Look Like?
Total weight loss in SURMOUNT-1 averaged 20.9% at week 72 on the 15 mg dose. Body composition analysis from subsets of participants showed roughly 60-70% of weight loss came from fat mass and 30-40% from lean mass. This ratio matters because too much lean mass loss accelerates sarcopenia.
The lean mass component included some muscle, some bone density, some water, and some glycogen. The true “muscle loss” portion is hard to pin down with standard DEXA but is generally estimated at 20-30% of total weight lost.
Protein intake (1.2-1.6 g/kg/day), resistance training (2-3 sessions/week), and adequate sleep matter throughout treatment. Participants who emphasized protein and lifting in observational follow-up of SURMOUNT-1 lost less muscle and ended with better metabolic outcomes.
What About Visceral Fat Specifically?
Visceral fat (the deep abdominal fat surrounding organs) drops faster than subcutaneous fat on tirzepatide. MRI studies show 25-35% reductions in visceral adipose tissue at 28-52 weeks, disproportionate to total weight loss.
This is why waist measurements often improve faster than weight on the scale. Visceral fat is the more metabolically harmful fat depot, so its preferential loss explains why metabolic improvements (insulin sensitivity, blood pressure, lipids) often outpace what weight loss alone would predict.
The pattern is similar to bariatric surgery and other significant weight-loss interventions: visceral fat goes first, subcutaneous fat goes more slowly.
What Does Life Look Like at Maintenance?
After reaching goal weight, daily life on tirzepatide maintenance is largely unremarkable. Appetite is still suppressed but less dramatically than during active weight loss. Meals are smaller. Snacking is rare. Energy is steady when nutrition is adequate.
Most patients describe a settled relationship with food after the first year. The “food noise” that dominated pre-treatment thinking remains quieter. Special occasions, vacations, and celebratory meals are tolerated normally; rebound binges are uncommon.
The medication continues to suppress appetite as long as it’s in the system. Stopping triggers appetite return within 2-4 weeks, which is why long-term maintenance is the standard approach.
Bottom line: Stopping leads to about 14% body weight regain over 12 months (SURMOUNT-4)
FAQ
How Fast Should I Expect to Lose Weight in the First Month?
Most patients lose 3-5 pounds in month one on the 2.5 mg starter dose. Some lose none. The starter dose is below the therapeutic range, so the first real weight loss phase begins in month two when titration reaches 5 mg.
Is It Normal to Lose Nothing for 2-3 Weeks?
Yes. Weight plateaus of 2-4 weeks are normal at any point in the trajectory. They reflect water shifts, metabolic adaptation, and body composition changes that don’t show on the scale. Trends over 8-12 weeks matter more than week-to-week numbers.
Why Am I Losing Slower Than the SURMOUNT-1 Average?
SURMOUNT-1 trial participants received intensive lifestyle support including monthly counseling, food logs, and structured exercise plans alongside the drug. Real-world loss tends to run 70-80% of trial averages without that support. Other factors include insulin resistance, sleep, age, and dose escalation pace.
When Do I Plateau Permanently on Tirzepatide?
True permanent plateaus typically appear around week 60-72 on a stable dose. Earlier plateaus usually break with dose adjustment, intake review, or addressing sleep and stress.
Is Tirzepatide Really Better Than Semaglutide for Weight Loss?
SURMOUNT-1 (20.9%) vs STEP 1 (14.9%) suggests yes for the average patient. SURPASS-2 directly compared the two in diabetes patients and showed greater weight loss on tirzepatide. Individual response varies, and some people lose more on semaglutide.
How Much Weight Comes Back If I Stop?
About 14% of body weight on average regains within 12 months of stopping (SURMOUNT-4 data). That’s roughly two-thirds of what was lost. Building habits during treatment helps but doesn’t fully prevent regain for most people.
Does Muscle Loss Matter on Tirzepatide?
Yes. About 25-40% of total weight lost is lean mass, similar to other weight loss approaches. Resistance training and adequate protein intake (1.2-1.6 g/kg/day) preserve more muscle during treatment. DEXA scans before and during treatment can track body composition.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
Tirzepatide for Men: How Results Differ From Women
The clinical trials for tirzepatide included both men and women, and the headline results, average weight loss of around 20 percent of body weight…
Tirzepatide for Women Over 50: Menopause, Metabolism, and What to Expect
Women over 50 who start tirzepatide are working with a set of biological variables that don’t exist in younger patients, and understanding those variables…
Regaining Weight After Stopping Tirzepatide: What to Expect
Weight regain after stopping tirzepatide is one of the most searched and least clearly answered questions in the GLP-1 space. Patients want to know…
